Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTC: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that it has received approval from The Nasdaq Stock Market LLC (“Nasdaq”) to resume trading of its common stock on the Nasdaq Capital Market subject to Spruce regaining compliance with Nasdaq's minimum bid price requirement on or bef.
- 06/12/2025
|
Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTC: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2025 and provided corporate updates. “With no FDA-approved treatments currently available to treat MPS IIIB, TA-ERT has the potential to be a groundbreaking advancement for patients a.
- 05/06/2025
|
Spruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript)
- Spruce Biosciences, Inc. (NASDAQ:SPRB ) Corporate Update Conference Call April 15, 2025 8:30 AM ET Company Participants Samir Gharib - President and CFO Javier Szwarcberg - CEO Kirk Ways - Chief Medical Officer Conference Call Participants Joe Schwartz - Leerink Partners Jon Wolleben - JMP Leland Gershell - Oppenheimer Ram Selvaraju - H.C. Wainwright Operator Welcome to the Spruce Biosciences Investor Call [Operator Instructions].
- 04/15/2025
|
Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the company's new corporate strategy and acquisition of tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). “This is truly a transformative moment for Spruce as we focus ou.
- 04/15/2025
|
Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why
- Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 12/13/2024
|
Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder
- On Tuesday, Spruce Biosciences, Inc. SPRB revealed topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH.
- 12/11/2024
|
Spruce Biosciences to wind down investment for genetic disorder drug
- Spruce Biosciences said on Tuesday it will wind down investments for its genetic disorder drug after it failed to meet the main goal in a mid-stage study.
- 12/10/2024
|
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological and endocrine disorders with significant unmet medical need, today announced topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH. “We are very grateful to all the patients, families, investigators, and the e.
- 12/10/2024
|
Spruce Biosciences, Inc. (SPRB) Reports Q3 Loss, Lags Revenue Estimates
- Spruce Biosciences, Inc. (SPRB) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.30 per share a year ago.
- 11/11/2024
|
Spruce Biosciences, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 11/04/2024
|
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
- LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 11/03/2024
|
Spruce Biosciences, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Take Part
- LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 11/02/2024
|
Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Guggenheim Securities Healthcare Innovation Conference on November 11, 2024, at 3:30 p.m. ET. Interested parties can access the live webca.
- 10/28/2024
|
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
- LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/27/2024
|
Spruce Biosciences, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / October 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/26/2024
|
Spruce Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Shareholder Participation
- LOS ANGELES, CA / ACCESSWIRE / October 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/20/2024
|
Investors Are Encouraged To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
- LOS ANGELES, CA / ACCESSWIRE / October 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/19/2024
|
Spruce Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Shareholders To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / October 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/18/2024
|
Investors Are Encouraged To Join The Schall Law Firm's Inquiry Into Spruce Biosciences Inc For Securities Law Violations
- LOS ANGELES, CA / ACCESSWIRE / October 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/17/2024
|
Spruce Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Shareholder Participation
- LOS ANGELES, CA / ACCESSWIRE / October 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/14/2024
|
Investors Are Encouraged To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
- LOS ANGELES, CA / ACCESSWIRE / October 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/13/2024
|
Spruce Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Shareholders To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / October 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/12/2024
|
Investors Are Encouraged To Join The Schall Law Firm's Inquiry Into Spruce Biosciences Inc For Securities Law Violations
- LOS ANGELES, CA / ACCESSWIRE / October 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/11/2024
|
Spruce Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / October 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/10/2024
|
Investors Are Encouraged To Join The Schall Law Firm's Inquiry Into Spruce Biosciences Inc For Securities Law Violations
- LOS ANGELES, CA / ACCESSWIRE / October 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/09/2024
|
Spruce Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / October 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/08/2024
|
Investors Are Encouraged To Join The Schall Law Firm's Inquiry Into Spruce Biosciences Inc For Securities Law Violations
- LOS ANGELES, CA / ACCESSWIRE / October 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/07/2024
|
Spruce Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / October 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/06/2024
|
Investors Are Invited By The Schall Law Firm To Join An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
- LOS ANGELES, CA / ACCESSWIRE / October 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/05/2024
|
Spruce Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Encourages Shareholders To Participate
- LOS ANGELES, CA / ACCESSWIRE / October 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/04/2024
|
The Schall Law Firm Is Inquiring Into Spruce Biosciences Inc For Securities Law Violations And Investors With Losses Should Reach Out
- LOS ANGELES, CA / ACCESSWIRE / October 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/03/2024
|
Spruce Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Urged To Help The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / October 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/02/2024
|
The Schall Law Firm Encourages Investors To Join An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
- LOS ANGELES, CA / ACCESSWIRE / October 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 10/01/2024
|
Spruce Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / September 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/30/2024
|
The Schall Law Firm Encourages Investor Participation In An Inquiry Into Spruce Biosciences Inc For Violating Securities Laws
- LOS ANGELES, CA / ACCESSWIRE / September 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/29/2024
|
Spruce Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And Impacted Shareholders Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / September 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/28/2024
|
The Schall Law Firm Invites Investor Participation In An Inquiry Into Spruce Biosciences Inc For Violating Securities Laws
- LOS ANGELES, CA / ACCESSWIRE / September 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/27/2024
|
Spruce Biosciences, Inc. Is Being Investigated For Securities Fraud And Stockholders With Losses Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / September 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/26/2024
|
The Schall Law Firm Invites Investor Participation In An Inquiry Into Spruce Biosciences Inc For Possible Securities Law Violations
- LOS ANGELES, CA / ACCESSWIRE / September 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/25/2024
|
Spruce Biosciences, Inc. Is Being Investigated For Securities Fraud And Stockholders With Losses Are Urged By The Schall Law Firm To Help
- LOS ANGELES, CA / ACCESSWIRE / September 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/24/2024
|
Investors Should Contact The Schall Law Firm About An Inquiry Into Spruce Biosciences Inc For Violating Securities Laws
- LOS ANGELES, CA / ACCESSWIRE / September 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/23/2024
|
The Schall Law Firm Is Investigating Spruce Biosciences, Inc. For Possible Securities Fraud And Shareholders Are Urged To Lend A Hand
- LOS ANGELES, CA / ACCESSWIRE / September 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/22/2024
|
Spruce Biosciences Inc May Have Violated Securities Laws And The Schall Law Firm Seeks Investor Participation In An Inquiry
- LOS ANGELES, CA / ACCESSWIRE / September 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/21/2024
|
Stockholders Are Urged To Help The Schall Law Firm Investigate Spruce Biosciences, Inc. For Possible Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / September 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/20/2024
|
Spruce Biosciences Inc May Have Violated Securities Laws And The Schall Law Firm Invites Investor Participation In An Inquiry
- LOS ANGELES, CA / ACCESSWIRE / September 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/19/2024
|
The Schall Law Firm Is Looking Into Spruce Biosciences, Inc. For Securities Fraud And Stockholders Should Reach Out
- LOS ANGELES, CA / ACCESSWIRE / September 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/18/2024
|
Investors Are Invited To Assist The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
- LOS ANGELES, CA / ACCESSWIRE / September 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/17/2024
|
The Schall Law Firm Is Looking Into Spruce Biosciences, Inc. For Possible Securities Fraud And The Firm Seeks Shareholder Participation
- LOS ANGELES, CA / ACCESSWIRE / September 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/16/2024
|
Spruce Biosciences Inc May Have Committed Securities Law Violations And Investors Are Encouraged By The Schall Law Firm To Take Part
- LOS ANGELES, CA / ACCESSWIRE / September 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/15/2024
|
The Schall Law Firm Urges Shareholders In Spruce Biosciences, Inc. To Contribute To A Securities Fraud Inquiry
- LOS ANGELES, CA / ACCESSWIRE / September 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/14/2024
|
Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm For Possible Securities Law Violations And Investors Can Take Part
- LOS ANGELES, CA / ACCESSWIRE / September 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/13/2024
|
The Schall Law Firm Is Inquiring Into Whether Spruce Biosciences, Inc. Committed Securities Fraud And Stockholders Are Urged To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / September 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/12/2024
|
Investors With Losses In Spruce Biosciences Inc Should Join The Schall Law Firm In An Investigation Into Securities Law Violations
- LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/11/2024
|
The Schall Law Firm Is Looking Into Whether Spruce Biosciences, Inc. Committed Securities Fraud And The Firm Wants Affected Shareholders To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / September 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/10/2024
|
Spruce Biosciences Inc May Have Violated Securities Regulations And Investors Are Invited To Help The Schall Law Firm's Inquiry
- LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/09/2024
|
The Schall Law Firm Urges Stockholder Participation In An Investigation Into Whether Spruce Biosciences, Inc. Committed Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/07/2024
|
Spruce Biosciences Inc Is Being Looked Into For Possibly Violating Securities Laws And Shareholders Are Invited To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/06/2024
|
The Schall Law Firm Urges Investors With Losses In Spruce Biosciences Inc. To Reach Out About An Inquiry Into Possible Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/05/2024
|
Spruce Biosciences Inc May Have Violated Securities Regulations And Stockholders Are Encouraged To Assist The Schall Law Firm's Investigation
- LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/04/2024
|
The Schall Law Firm Seeks Shareholder Participation In An Inquiry Into Spruce Biosciences Inc. For Possible Securities Related Infractions
- LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/03/2024
|
Spruce Biosciences Inc May Have Engaged In Illegal Practices And Affected Investors Are Invited To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/02/2024
|
An Inquiry Has Been Launched Into Whether Spruce Biosciences Inc. Violated Securities Regulations And Stockholders Are Encouraged To Assist
- LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 09/01/2024
|
Spruce Biosciences Inc Is Being Investigated For Fraud And The Schall Law Firm Seeks Investor Participation
- LOS ANGELES, CA / ACCESSWIRE / August 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/31/2024
|
The Schall Law Firm Is Looking Into Potential Securities Law Violations By Spruce Biosciences Inc. And Stakeholders Should Reach Out
- LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/30/2024
|
Spruce Biosciences Is Being Inquired Into For Securities Fraud And Investors Are Encouraged By The Schall Law Firm To Take Part
- LOS ANGELES, CA / ACCESSWIRE / August 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/29/2024
|
Shareholders Are Invited By The Schall Law Firm To Join An Investigation Into Whether Spruce Biosciences Inc Breached Securities Laws
- LOS ANGELES, CA / ACCESSWIRE / August 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/28/2024
|
Spruce Biosciences, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - SPRB
- NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.
- 08/28/2024
|
Spruce Biosciences Inc Might Have Committed Securities Law Violations And The Schall Law Firm Seeks Investors To Help
- LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/27/2024
|
SPRB ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Spruce Biosciences, Inc.
- NEW YORK, NY / ACCESSWIRE / August 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.
- 08/27/2024
|
Shareholders In Spruce Biosciences Inc Are Encouraged To Contact The Schall Law Firm About Possible Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / August 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/26/2024
|
Did Spruce Biosciences, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SPRB
- NEW YORK, NY / ACCESSWIRE / August 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.
- 08/25/2024
|
The Schall Law Firm Is Investigating Spruce Biosciences Inc For Potential Securities Law Violations And Investors Are Urged To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / August 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/25/2024
|
SPRB STOCK ALERT: Levi & Korsinsky Notifies Spruce Biosciences, Inc. Investors of an Ongoing Investigation
- NEW YORK, NY / ACCESSWIRE / August 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.
- 08/24/2024
|
An Securities Fraud Inquiry Has Been Opened Into Spruce Biosciences Inc And The Schall Law Firm Seeks Shareholder Participation
- LOS ANGELES, CA / ACCESSWIRE / August 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/24/2024
|
Spruce Biosciences, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Spruce Biosciences (SPRB)
- NEW YORK, NY / ACCESSWIRE / August 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.
- 08/23/2024
|
Investors In Spruce Biosciences Inc Are Urged To Join The Schall Law Firm In An Investigation For Possible Securities Law Violations
- LOS ANGELES, CA / ACCESSWIRE / August 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/23/2024
|
Lost Money on Spruce Biosciences, Inc. (SPRB)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
- NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.
- 08/22/2024
|
The Schall Law Firm Invites Shareholders To Participate In An Inquiry Into Spruce Biosciences Inc For Potential Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/22/2024
|
Lost Money on Spruce Biosciences, Inc. (SPRB)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.
- 08/21/2024
|
Investors Who Lost Money on Spruce Biosciences, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - SPRB
- NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.
- 08/20/2024
|
Shareholders Are Invited To Contact The Schall Law Firm About Spruce Biosciences Inc's Potential Securities Law Violations
- LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/20/2024
|
Spruce Biosciences, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - SPRB
- NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.
- 08/19/2024
|
Levi & Korsinsky Reminds Shareholders of an Investigation into Spruce Biosciences, Inc. (SPRB) Regarding Potential Securities Fraud Allegations
- NEW YORK, NY / ACCESSWIRE / August 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.
- 08/18/2024
|
Levi & Korsinsky Reminds Spruce Biosciences Investors of the Ongoing Investigation into Potential Violations of Securities Laws - SPRB
- NEW YORK, NY / ACCESSWIRE / August 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.
- 08/17/2024
|
Lost Money on Spruce Biosciences, Inc.(SPRB)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
- NEW YORK, NY / ACCESSWIRE / August 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.
- 08/16/2024
|
Investors With Losses In Spruce Biosciences Inc Invited To Contact Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/16/2024
|
Levi & Korsinsky Reminds Shareholders of an Investigation into Spruce Biosciences, Inc. (SPRB) Regarding Potential Securities Fraud Allegations
- NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.
- 08/15/2024
|
Investors Who Lost Money In Spruce Biosciences Inc Encouraged To Contact Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/15/2024
|
Investors Who Incurred Losses Urged To Contact Schall Law Firm Investigating Spruce Biosciences Inc
- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/14/2024
|
SPRB ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Spruce Biosciences, Inc. investment
- NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ:SPRB) concerning possible violations of federal securities laws. Spruce is the subject of a Seeking Alpha report published on March 13, 2024.
- 08/14/2024
|
Investors Who Have Incurred Losses Are Urged To Make Contact As The Schall Law Firm Investigates Spruce Biosciences Inc
- LOS ANGELES, CA / ACCESSWIRE / August 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/13/2024
|
Investors Who Have Suffered Losses Are Urged To Make Contact As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm
- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/12/2024
|
Spruce Biosciences, Inc. (SPRB) Reports Q2 Loss, Tops Revenue Estimates
- Spruce Biosciences, Inc. (SPRB) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.32 per share a year ago.
- 08/12/2024
|
Investors With Losses Are Encouraged To Reach Out As Spruce Biosciences Inc Is Under The Schall Law Firm's Investigation
- LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/09/2024
|
Investors With Losses Are Urged To Make Contact As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/08/2024
|
Investors Who Have Incurred Losses Are Encouraged To Reach Out As Spruce Biosciences Inc Is Under Investigation By The Schall Law Firm
- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/07/2024
|
Investors With Losses Are Urged To Initiate Dialogue As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/06/2024
|
Investors With Losses Are Urged To Initiate Dialogue As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/30/2024
|
Investors With Losses Are Urged To Initiate Dialogue As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/29/2024
|
Investors With Losses Encouraged To Initiate Dialogue As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/26/2024
|
Investors With Losses Encouraged To Initiate Dialogue As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / July 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/25/2024
|
Investors With Losses Encouraged To Initiate Dialogue As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / July 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/24/2024
|
Investors With Losses Encouraged To Initiate Dialogue As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / July 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/23/2024
|
Investors With Losses Encouraged To Initiate Dialogue As Spruce Biosciences Inc Is Being Investigated By The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / July 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/22/2024
|
The Schall Law Firm Is Investigating Spruce Biosciences Incorporated And Encourages Investors With Losses To Initiate Dialogue
- LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/19/2024
|
Investors With Losses Are Urged To Start Conversation, Spruce Biosciences Incorporated Is Under Probe By The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/18/2024
|
Spruce Biosciences Inc Is Under Investigation By The Schall Law Firm, Investors With Losses Are Urged To Begin Conversations
- LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/17/2024
|
Investors With Losses Encouraged To Initiate Dialogue, Spruce Biosciences Inc Being Investigated By The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / July 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/16/2024
|
Spruce Biosciences Inc Under Examination By The Schall Law Firm Encouraging Investors With Losses To Start Conversation
- LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/15/2024
|
Spruce Biosciences Inc Is Under Investigation By The Schall Law Firm Which Encourages Investors With Losses To Begin Conversation
- LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/13/2024
|
The Schall Law Firm Is Investigating Spruce Biosciences Inc And Invites Investors With Losses To Initiate Dialogue
- LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/12/2024
|
Spruce Biosciences Inc Under Investigation By The Schall Law Firm Encouraging Investors With Losses To Start Conversation
- LOS ANGELES, CA / ACCESSWIRE / July 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/11/2024
|
The Schall Law Firm Initiates Inquiry Into Spruce Biosciences Inc And Urges Investors With Losses To Begin Dialogue
- LOS ANGELES, CA / ACCESSWIRE / July 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/10/2024
|
The Schall Law Firm Begins Investigation Into Spruce Biosciences Inc And Encourages Investors With Losses To Start Conversation
- LOS ANGELES, CA / ACCESSWIRE / July 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/09/2024
|
The Schall Law Firm Starts Inquiry Into Spruce Biosciences Inc And Calls On Investors With Losses To Initiate Dialogue
- LOS ANGELES, CA / ACCESSWIRE / July 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/08/2024
|
The Schall Law Firm Starts Scrutiny Of Spruce Biosciences Inc And Promotes Investors With Losses To Begin Communication
- LOS ANGELES, CA / ACCESSWIRE / July 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/07/2024
|
Investigation Into Spruce Biosciences Inc Is Launched By The Schall Law Firm And It Urges Investors With Losses To Commence Contact
- LOS ANGELES, CA / ACCESSWIRE / July 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/06/2024
|
The Schall Law Firm Begins Examination Into Spruce Biosciences Inc And Motivates Investors With Losses To Initiate Interaction
- LOS ANGELES, CA / ACCESSWIRE / July 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/05/2024
|
The Schall Law Firm Initiates Inquiry Into Spruce Biosciences Inc And Encourages Investors With Losses To Establish Communication
- LOS ANGELES, CA / ACCESSWIRE / July 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/03/2024
|
Investigation Into Spruce Biosciences Inc Launched By The Schall Law Firm And Investors With Losses Are Encouraged To Set Up Communication
- LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 07/02/2024
|
The Schall Law Firm Initiates Investigation Into Spruce Biosciences Inc And Urges Investors With Losses To Establish Communication
- LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/28/2024
|
The Schall Law Firm Begins Probe Into Allegations Against Spruce Biosciences Inc And Encourages Investors Who Suffered Losses To Initiate Contact
- LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/26/2024
|
The Schall Law Firm Begins Probe Into Spruce Biosciences Inc And Encourages Investors Who Suffered Losses To Initiate Contact
- LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/25/2024
|
The Schall Law Firm Initiates Investigation Into Spruce Biosciences Inc And Urges Investors With Losses To Establish Communication
- LOS ANGELES, CA / ACCESSWIRE / June 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/24/2024
|
The Schall Law Firm Begins Probe Into Spruce Biosciences Inc And Encourages Investors With Losses To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/23/2024
|
The Schall Law Firm Initiates Investigation Into Spruce Biosciences Inc And Urges Investors With Losses To Connect
- LOS ANGELES, CA / ACCESSWIRE / June 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/22/2024
|
The Schall Law Firm Begins Probe Into Spruce Biosciences Inc And Encourages Investors With Losses To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/21/2024
|
The Schall Law Firm Initiates Investigation Into Spruce Biosciences Inc And Urges Investors With Losses To Make Contact
- LOS ANGELES, CA / ACCESSWIRE / June 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/20/2024
|
The Schall Law Firm Is Conducting A Probe Into Spruce Biosciences Inc They Encourage Investors Who Have Incurred Losses To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/19/2024
|
The Schall Law Firm Is Undertaking An Investigation Into Spruce Biosciences Inc They Urge Investors Who Have Suffered Losses To Make Contact
- LOS ANGELES, CA / ACCESSWIRE / June 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/18/2024
|
The Schall Law Firm Is Conducting A Probe Into Spruce Biosciences Inc They Encourage Investors Who Have Incurred Losses To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/17/2024
|
The Schall Law Firm Is Undertaking An Investigation Into Spruce Biosciences, Inc.: They Urge Investors Who Have Suffered Losses To Make Contact
- LOS ANGELES, CA / ACCESSWIRE / June 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/11/2024
|
The Schall Law Firm Is Carrying Out An Investigation Into Spruce Biosciences, Inc.: They Urge Investors Who Have Suffered Losses To Contact Them
- LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/09/2024
|
The Schall Law Firm Is Conducting A Probe Into Spruce Biosciences, Inc.: They Encourage Investors Who Have Experienced Losses To Get In Touch
- LOS ANGELES, CA / ACCESSWIRE / June 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/08/2024
|
Spruce Biosciences, Inc. Is Under Investigation By The Schall Law Firm: Investors Who Have Incurred Losses Are Encouraged To Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/07/2024
|
Spruce Biosciences, Inc. Is Being Probed By The Schall Law Firm: Investors Who Have Suffered Losses Are Urged To Make Contact
- LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/06/2024
|
Spruce Biosciences Recognized as a Bay Area Best Place to Work
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, announced that the San Francisco Business Times and the Silicon Valley Business Journal have recognized the company as a Best Place to Work in 2024. “We are thrilled to be named as a Best Place to Work in the Bay Area, which is a testame.
- 06/06/2024
|
Spruce Biosciences, Inc. Under Investigation by Schall Law Firm: Investors with Losses Encouraged to Reach Out
- LOS ANGELES, CA / ACCESSWIRE / June 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/05/2024
|
The Schall Law Firm Initiates Investigation into Allegations Against Spruce Biosciences, Inc. and Urges Investors Suffering Losses to Connect
- LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/04/2024
|
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
- SOUTH SAN FRANCISCO, Calif. & MUNICH--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, and HMNC Brain Health GmbH (“HMNC”), a global precision psychiatry biopharma company, announced today a strategic collaboration to develop Spruce's investigational product candidate, tildacerfont, a second-generation.
- 06/04/2024
|
SPRB ONGOING INVESTIGATION UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/03/2024
|
Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine disorders with significant unmet medical need, presented results from its Phase 2 POWER study of tildacerfont, a second-generation CRF1 receptor antagonist, for the treatment of polycystic ovary syndrome (PCOS) at the 2024 Annual Meeting of the Endocrine Society (ENDO 2024). “There is a significant u.
- 06/03/2024
|
IMPORTANT ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/02/2024
|
IMPORTANT ACTION UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / June 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 06/01/2024
|
IMPORTANT ACTION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/31/2024
|
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. he investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/30/2024
|
Spruce Biosciences to Participate in the Jefferies Global Healthcare Conference
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 5:00 p.m. ET. Interested parties can access the live webcast here. An archived copy of the.
- 05/23/2024
|
Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that three submitted abstracts were accepted for the 106th Annual Meeting of the Endocrine Society (ENDO 2024) taking place June 1-4, 2024, in Boston. In a poster presentation, the company will present final results from its Phase 2.
- 05/22/2024
|
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/19/2024
|
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/18/2024
|
IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/17/2024
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/16/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 05/15/2024
|
Spruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates
- Spruce Biosciences, Inc. (SPRB) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.40 per share a year ago.
- 05/13/2024
|
Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2024 and provided corporate updates. “We are encouraged by key learnings from analyses of data from our CAHmelia-203 clinical trial in adult CAH patients with severe hyperandroge.
- 05/13/2024
|
Spruce Biosciences to Participate in May Investor Conferences
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in two upcoming investor conferences taking place in May. The JMP Securities Life Sciences Conference Date: May 13-14, 2024 Format: Fireside chat (May 14.
- 05/01/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/30/2024
|
Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that an accepted abstract highlighting baseline characteristics from the company's CAHptain Phase 2 study evaluating tildacerfont in children and adolescents with congenital adrenal hyperplasia (CAH) will be presented at the Pediatri.
- 04/30/2024
|
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the Pediatric Endocrine Society (PES) 2024 Annual Meeting taking place May 2-5, 2024, in Chicago, IL. In the poster presentation, Paul Thornton, M.B.B.S., will highlig.
- 04/22/2024
|
IMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/19/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/05/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB
- NEW YORK , April 4, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or the "Company") (NASDAQ: SPRB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/04/2024
|
ONGOING SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/04/2024
|
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/03/2024
|
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/01/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / March 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ: SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 03/30/2024
|
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / March 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 03/29/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / March 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 03/28/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB
- NEW YORK , March 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or the "Company") (NASDAQ: SPRB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/27/2024
|
Spruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Know
- Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 03/27/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / March 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 03/27/2024
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / March 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 03/26/2024
|
Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why
- Spruce Biosciences' (SPRB) CAHmelia-203 phase IIb study of tildacerfont in adult patients with CAH fails to meet the primary efficacy endpoint.
- 03/21/2024
|
Why Is Spruce Biosciences (SPRB) Stock Down 78% Today?
- Spruce Biosciences (NASDAQ: SPRB ) stock is falling hard on Thursday after the biopharmaceutical company posted two new updates for investors. The first big update that has investors in SPRB stock reeling are the results of a Phase 2b clinical trial of tildacerfont in adult patients with classic congenital adrenal hyperplasia ( CAH ).
- 03/14/2024
|
Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 2:40 p.m. ET. Interested parties can access the live webcast here.
- 01/30/2024
|
Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)
- The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
- 10/20/2023
|
Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023, at 3:30 p.m. ET. Interested parties can access the live webcast here.
- 08/28/2023
|
Best Penny Stocks To Buy? 3 To Watch With Targets Up To 400%
- Analysts like these penny stocks but is it time to buy or not? The post Best Penny Stocks To Buy?
- 02/23/2023
|
Penny Stocks To Buy? 4 Cheap Stocks To Watch Right Now
- High volume penny stocks to watch right now. The post Penny Stocks To Buy?
- 02/09/2023
|
Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
- SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #Tildacerfont--Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
- 08/30/2022
|
Spruce Biosciences Stock (SPRB): Why The Price Jumped
- The stock price of Spruce Biosciences Inc (NASDAQ: SPRB) increased by 13.48% in the most recent trading session. This is why it happened.
- 01/07/2022
|
5 Beaten-Down Biotech Bets to Bounce Back in 2022
- Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.
- 12/31/2021
|
Short Squeeze Penny Stocks To Buy For Under $5 If You Like Risk
- Penny stocks with high short interest gaining plenty of attention in the stock market today. The post Short Squeeze Penny Stocks To Buy For Under $5 If You Like Risk appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/27/2021
|
Best Penny Stocks To Buy? 5 Short Squeeze Stocks To Watch Right Now
- 5 penny stocks with high short interest to add to your watch list in December. The post Best Penny Stocks To Buy?
- 12/21/2021
|
Spruce Biosciences Stock (SPRB): Why The Price Surged
- The stock price of Spruce Biosciences Inc (NASDAQ: SPRB) increased by 102.82% in the previous trading session. This is why it happened.
- 12/20/2021
|
Spruce Biosciences, Inc. (SPRB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
- Spruce Biosciences, Inc. (SPRB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
- 12/14/2021
|
5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates
- Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.
- 08/06/2021
|
Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors
- Dr. Ways' Expertise in Late-Stage Clinical Development in Therapeutics Areas of High Unmet Medical Meet Supports Spruce's Goal to Expand Portfolio of Indications for Tildacerfont San Francisco, Calif. – June 24, 2021 – Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced the appointment of Kirk Ways, M.D.
- 06/24/2021
|
Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors
- SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors
- 06/24/2021
|
Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism
- Tildacerfont was Evaluated in Two Phase 2 Open-Label Studies in Adults with Classic Congenital Adrenal Hyperplasia (CAH) Data Demonstrated Normalization or Trend to Normalization in Key Hormone Biomarkers
- 06/21/2021
|
Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism
- SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism
- 06/21/2021
|
Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at 23rd European Congress of Endocrinology
- SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #ECE2021--Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at 23rd European Congress of Endocrinology
- 05/24/2021
|
Spruce Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Updates
- SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Updates
- 05/12/2021
|
Spruce Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Recent Corporate Updates
- SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Recent Corporate Updates
- 03/22/2021
|
Spruce Biosciences Added to Russell 2000®, 3000® and Microcap® Indexes
- SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Added to Russell 2000®, 3000® and Microcap® Indexes
- 12/17/2020
|
